CN103122396B - 一种人巨细胞病毒hcmv检测试剂盒 - Google Patents
一种人巨细胞病毒hcmv检测试剂盒 Download PDFInfo
- Publication number
- CN103122396B CN103122396B CN201310009151.9A CN201310009151A CN103122396B CN 103122396 B CN103122396 B CN 103122396B CN 201310009151 A CN201310009151 A CN 201310009151A CN 103122396 B CN103122396 B CN 103122396B
- Authority
- CN
- China
- Prior art keywords
- hcmv
- target polynucleotide
- kit
- sequence
- pcr reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract description 66
- 239000000523 sample Substances 0.000 claims abstract description 71
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 34
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 34
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 34
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 27
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 27
- 239000002157 polynucleotide Substances 0.000 claims abstract description 27
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 19
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 19
- 206010011831 Cytomegalovirus infection Diseases 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 8
- 238000012360 testing method Methods 0.000 claims description 41
- 238000001514 detection method Methods 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 27
- 230000003321 amplification Effects 0.000 claims description 23
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 4
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 claims description 4
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 claims description 4
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 8
- 210000002700 urine Anatomy 0.000 abstract description 7
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 abstract description 5
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 abstract description 5
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 abstract description 5
- 210000005259 peripheral blood Anatomy 0.000 abstract description 4
- 239000011886 peripheral blood Substances 0.000 abstract description 4
- 238000013399 early diagnosis Methods 0.000 abstract description 3
- 239000007788 liquid Substances 0.000 abstract description 3
- 238000003752 polymerase chain reaction Methods 0.000 abstract 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 239000001103 potassium chloride Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 20
- 239000012925 reference material Substances 0.000 description 14
- 241000700605 Viruses Species 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 8
- 239000013642 negative control Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000009835 boiling Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001917 fluorescence detection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000000703 high-speed centrifugation Methods 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 206010062343 Congenital infection Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310009151.9A CN103122396B (zh) | 2013-01-10 | 2013-01-10 | 一种人巨细胞病毒hcmv检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310009151.9A CN103122396B (zh) | 2013-01-10 | 2013-01-10 | 一种人巨细胞病毒hcmv检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103122396A CN103122396A (zh) | 2013-05-29 |
CN103122396B true CN103122396B (zh) | 2014-08-13 |
Family
ID=48453537
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310009151.9A Active CN103122396B (zh) | 2013-01-10 | 2013-01-10 | 一种人巨细胞病毒hcmv检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103122396B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103725800B (zh) * | 2014-01-15 | 2015-03-11 | 湖南圣维尔医学检验所有限公司 | 一种人腺病毒检测试剂盒 |
CN103740832B (zh) * | 2014-01-15 | 2016-03-09 | 湖南圣湘生物科技有限公司 | 一种新型隐球菌检测试剂盒 |
CN107058612A (zh) * | 2016-12-22 | 2017-08-18 | 王洋 | 一种样本直接加入的hcmv dna一步法测定试剂盒 |
CN109022620A (zh) * | 2018-08-27 | 2018-12-18 | 郑州安图生物工程股份有限公司 | 一种用于检测人巨细胞病毒的试剂盒 |
CN111500779A (zh) * | 2020-05-06 | 2020-08-07 | 深圳康美生物科技股份有限公司 | 基于荧光pcr或质谱检测人巨细胞病毒的试剂盒 |
CN114350858A (zh) * | 2022-02-08 | 2022-04-15 | 山东见微生物科技有限公司 | 检测ebv和hcmv病毒的引物探针组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101760560A (zh) * | 2008-10-23 | 2010-06-30 | 上海复星医药(集团)股份有限公司 | 一种人巨细胞病毒(hcmv)荧光pcr检测方法 |
CN102115794A (zh) * | 2009-12-30 | 2011-07-06 | 上海复星医学科技发展有限公司 | 含内参的hcmv荧光定量pcr检测试剂盒 |
CN102174660A (zh) * | 2011-02-25 | 2011-09-07 | 湖南圣湘生物科技有限公司 | 乙型肝炎病毒荧光定量pcr检测试剂盒 |
-
2013
- 2013-01-10 CN CN201310009151.9A patent/CN103122396B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101760560A (zh) * | 2008-10-23 | 2010-06-30 | 上海复星医药(集团)股份有限公司 | 一种人巨细胞病毒(hcmv)荧光pcr检测方法 |
CN102115794A (zh) * | 2009-12-30 | 2011-07-06 | 上海复星医学科技发展有限公司 | 含内参的hcmv荧光定量pcr检测试剂盒 |
CN102174660A (zh) * | 2011-02-25 | 2011-09-07 | 湖南圣湘生物科技有限公司 | 乙型肝炎病毒荧光定量pcr检测试剂盒 |
Non-Patent Citations (14)
Title |
---|
Angélica Lidia Distéfano 等.Human Cytomegalovirus: detection of congenital and perinatal nfection in Argentina.《BMC Pediatrics》.2004,第4卷1-8. |
Chou,S..M60926.《Genbank》.1993,全序列. |
Chou,S..M60927.《Genbank》.1993,全序列. |
Chou,S..M85228.《Genbank》.1993,全序列. |
Human Cytomegalovirus: detection of congenital and perinatal nfection in Argentina;Angélica Lidia Distéfano 等;《BMC Pediatrics》;20040623;第4卷;1-8 * |
M60926;Chou,S.;《Genbank》;19930802;全序列 * |
M60927;Chou,S.;《Genbank》;19930802;全序列 * |
M85228;Chou,S.;《Genbank》;19930802;全序列 * |
PEG-6000浓缩圆环病毒2型的研究;何锡忠 等;《上海农业学报》;20081231;第24卷(第4期);42-44 * |
Rasmussen,L. 等.U66425.《Genbank》.1996,全序列. |
U66425;Rasmussen,L. 等;《Genbank》;19960905;全序列 * |
人巨细胞病毒感染的检测方法;郭大东 等;《山东医药》;20051231;第45卷(第20期);66-67 * |
何锡忠 等.PEG-6000浓缩圆环病毒2型的研究.《上海农业学报》.2008,第24卷(第4期),42-44. |
郭大东 等.人巨细胞病毒感染的检测方法.《山东医药》.2005,第45卷(第20期),66-67. |
Also Published As
Publication number | Publication date |
---|---|
CN103122396A (zh) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103060473B (zh) | 一种疱疹类病毒ebv检测试剂盒 | |
CN103060451B (zh) | 一种肺炎支原体mp检测试剂盒 | |
CN103122396B (zh) | 一种人巨细胞病毒hcmv检测试剂盒 | |
CN102174660B (zh) | 乙型肝炎病毒荧光定量pcr检测试剂盒 | |
CN103740832B (zh) | 一种新型隐球菌检测试剂盒 | |
CN101701267A (zh) | 乙型肝炎病毒荧光定量pcr检测试剂盒及其应用 | |
CN103757134A (zh) | 非洲猪瘟病毒的荧光定量pcr检测试剂、试剂盒及其检测方法 | |
CN103642945B (zh) | 一种含内参照的高灵敏Epstein-Barr病毒荧光定量PCR试剂盒 | |
CN103509877A (zh) | 一种用于检测prv的荧光定量pcr试剂盒及其应用 | |
CN103060452B (zh) | 沙眼衣原体ct检测试剂盒 | |
CN106520984A (zh) | 一种铜绿假单胞菌核酸荧光pcr检测试剂盒及检测方法 | |
CN103725800B (zh) | 一种人腺病毒检测试剂盒 | |
CN103710465B (zh) | 一种乙型肝炎病毒基因分型pcr检测试剂盒 | |
CN109576397A (zh) | 一种人类免疫缺陷病毒1型核酸定量检测试剂盒 | |
CN103074428B (zh) | 一种结核分枝杆菌tb检测试剂盒 | |
CN102559930A (zh) | 一种荧光定量rt-pcr检测丙型肝炎病毒的试剂盒 | |
CN103074429B (zh) | 解脲脲原体uu检测试剂盒 | |
CN105779644B (zh) | 人巨细胞病毒的实时荧光核酸恒温扩增检测试剂盒 | |
CN103060453A (zh) | 淋球菌ng检测试剂盒 | |
CN101580883B (zh) | 呼吸道合胞病毒实时荧光pcr检测试剂盒 | |
CN103740834A (zh) | 一种白色念珠菌检测试剂盒 | |
CN102154523B (zh) | 检测人bk病毒核酸的引物与荧光探针及其应用 | |
CN105624311A (zh) | 单管中多重靶核酸的实时荧光pcr检测方法及其试剂盒 | |
CN104745722A (zh) | 一种用于检测水痘带状疱疹病毒的引物、探针和试剂盒 | |
CN103173565A (zh) | 低危型人乳头瘤病毒hpv6/11检测试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20141119 Address after: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee after: Hunan company limited of Sheng Weier medical test institute Address before: 410012 No. 198 west slope, Tongzi hi tech Industrial Development Zone, Hunan, Changsha Patentee before: Sansure Biotech Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Effective date: 20150512 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150512 Address after: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee after: Sansure Biotech Inc. Address before: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee before: Hunan company limited of Sheng Weier medical test institute |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Kit for detecting human cytomegalovirus (HCMV) Effective date of registration: 20170711 Granted publication date: 20140813 Pledgee: Ningbo free trade zone Terry with equity investment partnership (limited partnership)|Suzhou equity equity investment center (limited partnership)|Ningbo Meishan Bonded Port District, Jun and equity investment partnership (limited partnership)|Chen Bang Pledgor: Hunan Gene Technology Co.|Hunan San Xiang Biological Technology Co. Ltd. Registration number: 2017430000042 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee after: Shengxiang Biotechnology Co., Ltd Address before: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee before: Sansure Biotech Inc. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200217 Granted publication date: 20140813 Pledgee: Suzhou Lirui equity investment center (limited partnership)|Triton equity investment partnership (limited partnership)|JUNHE Tongrui equity investment partnership (limited partnership)|Chenbang Pledgor: SANSURE BIOTECH Inc. Registration number: 2017430000042 |